TRACON Pharmaceuticals Inc

NASDAQ:TCON   3:53:10 PM EDT
6.70
+0.18 (+2.76%)
Earnings Announcements

Tracon Pharmaceuticals Announces Results Of Independent Data Monitoring Committee Review Of Safety Data From Envasarc Pivotal Trial

Published: 06/01/2021 12:11 GMT
TRACON Pharmaceuticals Inc (TCON) - Tracon Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data From Envasarc Pivotal Trial.
Tracon Pharmaceuticals Inc - Independent Data Monitoring Committee for Envasarc Pivotal Trial Has Recommended That Trial Will Proceed As Planned.
Tracon Pharmaceuticals Inc - Expect Data Monitoring Committee to Review Additional Safety Data in Q3.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.31

More details on our Analysts Page.